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Abstract 
Forkhead box protein C2 (FOXC2) is a gene encoding a transcription factor that controls the generation of 
mesodermal tissue including vascular and lymphatic tissues. FOXC2 has previously been associated with 
EMT and tumor angiogenesis in various cancers. Moreover, a relationship between the expression of 
FOXC2 and poor prognosis has been reported in various cancers. We herein examined the 
clinicopathological significance of FOXC2 in oral tongue squamous cell carcinoma (OTSCC) and 
attempted to clarify the function of FOXC2 in OTSCC cell lines in vitro. The overexpression of FOXC2 
was more frequent in cancers with higher grades according to the pattern of invasion (grade 4 vs. 1-3; 
p<0.05). A correlation was observed between the expression of FOXC2 and that of VEGF-A and -C 
(VEGF-A; p<0.05, VEGF-C; p<0.001). The high-FOXC2 expression group had a significantly poorer 
prognosis than that of the low-expression group (p<0.001). Multivariate analysis indicated that the 
overexpression of FOXC2 may also be an independent prognostic factor, similar to N classification(N0 vs 
1/2;p<0.05), stage classification(stage I/II vs III/IV; p<0.05), pattern of invasion(grade 1-3vs 4; p<0.05), 
local recurrence(local recurrence (+) vs (-);p<0.01), and the overexpression of FOXC2 (FOXC2 
overexpression (-)vs.(+); p<0.05). In the OTSCC cell line analysis, the expression of FOXC2 was also 
associated with proliferation and invasion potential. These results strongly suggest that the overexpression 
of FOXC2 may be a potent predictor of survival in OTSCC patients.
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Introduction 
Oral squamous cell carcinoma (OSCC) is the most common malignant tumor of the head and neck 
regions and accounts for more than 90% of cancers in the oral cavity[1]. The oral tongue is the most 
common site of OSCC. The primary therapeutic modality for OSCC is surgery. Although recent advances 
in surgical techniques and anticancer agents have improved tumor regression and survival for patients with 
OSCC, wide surgical resection of OSCC inevitably causes various oral dysfunctions. Therefore, new 
treatment strategies are urgently needed.  
The presence of neck lymph node metastasis is strongly related to a poor prognosis in squamous cell 
carcinoma of the head and neck[2-4]. Moreover, previous studies reported that an alteration in the 
expression of adhesion-related molecules was associated with a poor prognosis in OSCC patients[5-8]. In 
addition, several tissue and biological markers have been identified as possible indicators of the tumor 
aggressiveness and metastatic capability of tumors9. Epithelial-mesenchymal transition (EMT), 
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angiogenesis, and lymphangiogenesis are known to be pivotal for tumor progression and metastasis in oral 
tongue squamous cell carcinoma (OTSCC)[10,11]. The initial steps in the sequential process of metastasis 
were previously found to be similar to EMT in which cells lose epithelial characteristics including cell 
adhesion and gain mesenchymal features including cell motility during embryogenesis and wound 
healing[12,13]. Acquiring the EMT, accompanied the functional loss of E-cadherin maintaining the 
intercellular adhesion, stimulates the dissemination of single tumor cells from primary sites through 
cell-to-cell contact, thereby endowing cells with metastatic abilities[12-14].  Angiogenesis and 
lymphangiogenesis are also crucial for tumor progression and nodal metastasis in OSCC[10]. Some of the 
main angiogenic and lymphangiogenic factors have been identified as vascular endothelial growth factor 
(VEGF)-A and VEGF receptor(VEGFR) 2, as well as the VEGF-C/-D and VFGFR3 systems, 
respectively[15,16]. 
Mesenchyme forkhead 1 (also known as Forkhead box protein C2, FOXC2) is a gene encoding a 
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transcription factor that controls the generation of mesodermal tissue such as vascular and lymphatic 
tissues[17,18]. FOXC2 was previously associated with EMT[19-23] and tumor angiogenesis[24,25] in 
various cancers. Although a relationship has already been reported between the expression of FOXC2 and 
poor prognosis in various cancers[21,26-29], those between the expression of FOXC2 and 
clinicopathological features in OSCC have not yet been investigated. 
    The purpose of this study was to determine the clinicopathological significance of FOXC2 in OTSCC 
and clarify the function of FOXC2 in OTSCC cell lines in vitro. We performed an immunohistochemical 
analysis to determine the relationships between the expression of FOXC2 and clinicopathological features 
in clinical OTSCC samples. We also examined the effects of FOXC2 expression on the proliferation and 




Materials and methods 
Patients  
The study protocol was approved by the ethics committee of Nagasaki University Graduate School of 
Biomedical Sciences. Paraffin-embedded sections were obtained from biopsy specimens of 61 patients with 
tongue squamous cell carcinoma who underwent radical surgery in our department. Tumor stages were 
classified according to the TNM classification of the International Union against Cancer, histological 
differentiation was defined according to the WHO classification, and invasion patterns were determined 
according to Yamamoto’s classification[30]. As controls, samples of a normal oral epithelium were 
obtained after informed consent from ten patients undergoing routine surgical removal of their third molars.  
 
Cell lines 
 Five human tongue squamous cell carcinoma cell lines (OSC20, HSC3, HSC4, SAS, and OSC20), and 
human keratinocyte cell line, HEKa as the control, were obtained from the Human Science Research 
Resource Bank (Osaka, Japan). These cells were cultured in Dulbbeco’s modified Eagle’s medium 
(DMEM)(Wako Pure Chemical industries, Ltd., Osaka, Japan) supplemented with 10% fetal bovine 
serum(FBS)(Sigma Chemical Co., St. Louis, MO, USA) under the conditions of 5％ CO2 in air. 
  
 
Immunohistochemical staining and evaluations 
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Serial 4-μm-thick specimens were taken from tissue blocks. Sections were deparaffinized in xylene, soaked 
in target retrieval solution buffer (Dako, Glostrup, Denmark), and placed in an autoclave at 121°C for 5 min 
for antigen retrieval. Endogenous peroxidase was blocked by incubating sections with 0.3% H2O2 in 
methanol for 30 min. Immunohistochemical staining was performed using the Envision system (Envision+, 
Dako, Carpinteria, CA). The primary antibody used was directed against FOXC2 (2H3, Abnova, Taipei 
City, Taiwan), VFGF-A, and VEGF-C(Santa Cruz Biotechnology, Inc., Texas, USA). Sections were 
incubated with the primary antibody overnight at 4°C. Reaction products were visualized by immersing the 
sections in diaminobenzidine (DAB) solution, and the samples were counterstained with Meyer’s 
hematoxylin and mounted. Negative controls were prepared by replacing the primary antibody with 
phosphate-buffered saline. The expression of FOXC2 was defined as the presence of specific staining 
mainly in the cytoplasm of tumor cells. The immunoreactivity was scored by HSCORE[31]. The HSCORE 
was scored in a semiquantitative fashion incorporating both the intensity and the distribution of specific 
staining. The evaluations were recorded as percentages of positively stained target cells in each of five 
intensity categories which were denoted as 0(no staining), 1+(weak), 2+(distinct), 3+(strong), 4+(minimal 
light transmission through the staining). For each tissue, a value designated the HSCORE was determined 
by summing the percentages of cells staining at each intensity multiplied by the weighted intensity of 
staining. The overexpression of immunoreactivity was defined as HSCORE ≥75[31]. 
 
RNA isolation and semiquantitative reverse transcription-polymerase chain reaction (RT-PCR) 
Total RNA was isolated with TRIzol Reagent (Invitrogen, Carlsbad, CA, USA) and first-strand cDNA 
was synthesized from 1 μg of total RNA using Oligo d (T) primer (Invitrogen) and ReverTra Ace (Toyobo, 
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Osaka, Japan). In the PCR analysis, cDNA was amplified by Taq DNA polymerase (Takara, Otsu, Japan). 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the endogenous expression standard. 
Each PCR program involved a 3-min initial denaturation step at 94°C, followed by 25 cycles (for FOXC2), 
or 19 cycles (for GAPDH) at 94°C for 30 s, 55°C for 30 s, and 72°C for 1 min, on a PCR Thermal Cycler 
MP (Takara). Primer sequences were as follows: 5’-TCACACATAGAGGCCAGCAG-3’ for FOXC2 (F); 
5’-CCCTCATCGCAGTGAAAAAT-3’ for FOXC2 (R); 5’-ATGTCGTGGAGTCTACTGGC-3’ for 
GAPDH (F); and 5’-TGACCTTGCCCACAGCCTTG-3’ for GAPDH (R). The amplified products were 
separated by electrophoresis on ethidium bromide-stained 2% agarose gels. Band intensity was quantified 
by Image J software. 
 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide(MTT) assay 
 Cells were seeded in a 96-well plate at a concentration of 5 x 103 per well and incubated for 24h. In the 
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MTT assay, cells were incubated with 0.5 mg/ml MTT (Sigma Chemical Co.). Four hours later, the medium 
was replaced with 100 μl dimethylsulfoxide (DMSO) (Sigma Chemical Co.) and vortexed for 10 min. 
Absorbance (A) was then recorded at 570 nm using Easy Reader 340 AT (SLT Labinstruments, Salzburg, 
Austria). Cell viability (%) was calculated as the percentage of progression potential in tongue squamous 
cell carcinoma cell lines. 
 
Invasion assay 
A BioCoat Matrigel invasion chamber (Becton Dickinson, Bedford, MA) was used for the invasion assay. 
This contained an internal chamber with an 8-μm porous membrane bottom that was coated with Matrigel. 
Six-well cell culture inserts and a 6-well multiwell companion plate were used for the experiment. The 
membranes were rehydrated with warm serum-free medium for 2 h. The internal chamber was filled with 
1.25 ×105 cells in medium containing 10% FBS as a chemoattractant. Cells were incubated for 72 h at 37°C 
in a 5% CO2 atmosphere. After the incubation, noninvading cells were removed from the top of the wells 
with a cotton swab, and cells that transferred to the inverse surface of the membrane were subjected to 
Diff-Quick staining(Sysmex International Reagents Co., Ltd. Kobe, Japan). As the control, The HEKa cell 
line was examined(date not shown). Cells were counted under a microscope at 100× magnification. As a 
control, cells that passed through a control chamber without Matrigel were counted. All experiments were 
performed in triplicates, and cell numbers were counted in at least 4 fields/well. The ratio of the cell count 
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that passed through the Matrigel chamber to the control cell count was defined as the invasion index, and 
was expressed as a percentage. 
 
Statistical analysis 
Statistical analysis was performed using StatMate® (ATMS Co., Tokyo, Japan). The relationship 
between the expression of FOXC2 and clinicopathological features was assessed by Fischer’s exact test. 
Continuous data are given as means ± standard deviation. Data sets were examined by a one-way analysis 
of variance (ANOVA) followed by Scheffe’s post-hoc test. Survival analysis was carried out with 
Kaplan-Meier curves and the related log-rank tests. Prognosis factors were assessed by the Cox proportion 
hazard model. The relationship between FOXC2 mRNA expression and the invasion/growth index was 
determined using Person’s correlation coefficient. P values less than 0.05 were considered significant.
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Results 
Relationships between FOXC2 expression and clinicopathological features 
Immunohistochemistry with an anti-FOXC2 polyclonal antibody was performed on samples obtained 
from 61 patients with oral tongue squamous cell carcinoma. Representative immunohistochemical stainings 
are shown in Figure 1A. The overexpression of FOXC2 was undetectable in the normal epithelium. FOXC2 
staining was mainly detected in the cytoplasm of tongue squamous cell carcinoma cells, and strong FOXC2 
staining was observed at the invasive front and diffuse invasive area (Fig. 1B). The overexpression of 
FOXC2 was detected more frequently in OSCC (22 of 61, 36.1%) than in the normal oral epithelium (0 of 
10, 0%; p<0.05). Furthermore, the overexpression of FOXC2 was more frequently observed in cancers with 
higher grades according to the pattern of invasion(grade 4 vs. 1-3; p<0.05, Table 1). Angiogenesis and 
lymphangiogenesis have been shown to play crucial roles in tumor progression and nodal metastasis in 
OSCC[10]. The family of vascular endothelial growth factors, including VEGF-A, VEGF-B, VEGF-C, 
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VEGF-D, VEGF-E, placental growth factor, and VEGF-F, was previously reported to be crucially involved 
in angiogenesis and lymphangiogenesis [33]. Of these, VEGF-A and -C expression levels were previously 
correlated with lymph node metastasis in esophageal squamous cell carcinoma[34]. We also examined the 
relationship between the expression of FOXC2 and that of VEGF-A and –C. Immunohistochemical 
staining of VEGF-A and –C was detected in the cytoplasm of both normal tissue and tumor cells (Fig. 1C 
and D). These proteins were found to be strongly expressed in the invasion front of the tumor. Correlations 
were also observed between the expression of FOXC2 and that of VEGF-A and –C (VEGF-A; p<0.001, 
VEGF-C; p<0.001). 
These results strongly suggest that the overexpression of FOXC2 may be a potent predictor of survival 




Relationship between FOXC2 expression and survival analysis 
     The 5-year disease-specific survival rates of OTSCC patients according to FOXC2 expression 
were plotted (Fig. 2). The high-FOXC2 expression group had a significantly poorer prognosis with 45.9% 
than that of the low-expression group with 97.2% (p<0.001). Moreover, for the purpose of examining the 
relationships between the expression of FOXC2 and clinicopathological features, we performed a 
univariate analysis using the log-rank test and multivariate analysis by the Cox proportion hazard model. 
Univariate analysis revealed that the prognosis of OTSCC patients could be predicted by N 
classification( N 0 vs.1/2; p<0.05), stage classification ( stage I/II vs. III/IV; p<0.05), pattern of invasion 
(grade 1-3 vs. 4; p<0.01), local recurrence (local recurrence (-)vs.(+); p<0.05), VEGF-A (VEGF-A 
(-)vs.(+); p<0.05), and FOXC2 overexpression (FOXC2 overexpression (-)vs.(+); p<0.01). Multivariate 
analysis also suggested that the overexpression of FOXC2 may also be an independent prognostic factor, 
similar to N classification(N0 vs 1/2;p<0.05), stage classification(stage I/II vs III/IV; p<0.05), pattern of 
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invasion(grade 1-3vs 4; p<0.05), local recurrence(local recurrence (+) vs (-);p<0.01), and the 
overexpression of FOXC2 (FOXC2 overexpression (-)vs.(+); p<0.05). These results also strongly suggest 
that the overexpression of FOXC2 may be a potent predictor of survival, similar to the clinicopathological 
features described above. 
 
Effect of FOXC2 expression on the proliferation and invasion potential of OTSCC cells 
Cell proliferation and invasion are basic characteristics of tumor progression and metastasis. To 
determine the effects of FOXC2 expression on proliferation and invasion potential in OTSCC cell lines, we 
performed the MTT and Matrigel invasion assays. At the mRNA level, the expression of FOXC2 was 
shown a tendency to be associated with invasion potential in OTSCC cell lines (p=0.066) (Fig. 3A and B). 
Moreover, a correlation was observed between the expression of FOXC2 and proliferation potential 
(p<0.05) (Fig. 3C). These results suggest that FOXC2 may play key roles in tumor proliferation and 
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invasion in OTSCC in vitro. 
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Discussion 
Recent several studies reported the clinicopathological and functional significance of FOXC2 in 
various cancers. In esophageal squamous cell carcinoma, the strong expression of FOXC2 was previously 
associated with an advanced tumor stage, lymph node metastasis, and lymphatic invasion[26]. Zhu et al. 
reported that the strong expression of FOXC2 correlated with differentiation, invasion depth, lymph node 
metastasis, and tumor stage in gastric cancer[28]. Furthermore, FOXC2 expression was previously 
correlated with lymph node metastasis in extrahepatic cholangiocarcinoma and colorectal cancer[21,35]. In 
glioblastoma cells, FOXC2 expression was also shown to enhance proliferation and invasion[36]. In the 
present study, we performed immunohistochemical analyses to determine the relationship between FOXC2 
expression and clinicopathological features in OTSCC patients. The results obtained showed that the 
overexpression of FOXC2 was also more frequent in cancers with higher grades according to the T 
classification (T 3/4 vs. 1/2; p<0.05), N classification (N0 vs. 1/2; p<0.01), staging (stage I/II vs. III/IV; 
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p<0.05), and invasive pattern (grade 4 vs. 1-3; p<0.05).  The results of the immunohistochemical 
examination revealed that FOXC2 staining was mainly detected in the cytoplasm and strong FOXC2 
staining was observed at the invasive front and diffuse invasive area. FOXC2 staining was also mainly 
detected in cytoplasmic cancer tissues in esophageal and gastric cancers and extrahepatic 
cholangiocarcinoma[21,26,28]. A previous study detected the nuclear, perinuclear, and cytosolic 
localization of FOXC2 in breast and colonic adenocaricinoma[25]. A previous study also demonstrated that 
FOXC2 staining patterns ranged from absent to faint cytoplasmic staining in 52% of cancer cases, 
moderate cytoplasmic staining in 37%, and strong cytoplasmic and/or nuclear staining (high) in 10%[19]. 
Therefore, further studies are needed to confirm the significance of the cytoplasmic staining of FOXC2 in 
OTSCC.  
In the present study, we also found a correlation between FOXC2 expression and poor prognosis in the 
5-year disease-specific survival rates. This result is consistent with previous findings in which FOXC2 
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expression was correlated with a poor prognosis in various cancers, including esophageal, gastric, and 
non-small cell lung cancer as well as extrahepatic cholangiocarcinoma[21,26-28]. In the present study, 
multivariate analysis with Cox proportion hazard model revealed that FOXC2 expression may be a 
significant independent prognostic factor similar to N classification, stage classification, pattern of invasion, 
local recurrence, and  expression of VEGF-A. These results suggest that FOXC2 expression levels could 
be used as a prognostic factor in OTSCC patients. 
In the OTSCC cell lines examined in the present study, FOXC2 expression was correlated with the 
proliferation potential and revealed a tendency to be associated with the invasion potential. Regarding 
FOXC2 expression and invasion potential, FOXC2 expression was has been associated with EMT[19-23]. 
The expression of matrix metalloproteinases 2 (MMP-2) and matrix metalloproteinases 9 (MMP-9) was 
found to be markedly higher in a high-FOXC2 expression group with esophageal cancer involving local 
invasion[26]. The knockdown of FOXC2 was previously shown to inhibit cell motility and invasion in 
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extrahepatic cholangiocarcinoma and also decrease the expression of EMT markers (N-cadherin, MMP-2, 
and Angiopoietin 2)[21]. A previous study demonstrated that the overexpression of FOXC2 activated 
lymphatic drainage and enhanced lymphatic invasion by metastasizing cells[26]. Additionally, FOXC2 
expression was reported to be induced in cells undergoing EMT and was triggered by a number of signals, 
including TGF-β1 and several EMT-inducing transcription factors, such as Snail, Twist, and Goosecoid[21]. 
FOXC2 also promoted mesenchymal differentiation during EMT and was correlated with the highly 
aggressive basal-like subtype of breast cancer[21]. Although the expression of FOXC2 was mainly 
observed in cells at the invasive front and diffuse invasive area and was correlated with invasive features 
using immunohistochemical and in vitro analyses in the present study, the precise mechanisms responsible 
remain unclear in OTSCC. Therefore, further studies are needed to elucidate the relationship between 
FOXC2 and invasion potential in OTSCC. 
     Angiogenesis and lymphangiogenesis are known to be crucial for tumor progression and nodal 
metastasis in OSCC[10]. The family of vascular endothelial growth factors, including VEGF-A, VEGF-B, 
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VEGF-C, VEGF-D, VEGF-E, placental growth factor, and VEGF-F, play crucial roles in angiogenesis and 
lymphangiogenesis[34]. Of these, VEGF-A and -C expression levels have been correlated with lymph node 
metastasis in esophageal squamous cell carcinoma[34]. Naruse et al. reported that VEGF-A may be related 
to tumor growth and VEGF-C to invasion[32]. FOXC2 was previously shown to play an important role in 
the migration and tubular transformation of vascular endothelial cells and also in tumor angiogenesis, 
which are known to be elicited by the activation of VEGF-A signaling[24,25]. In OSCC, Prospero 
homeobox 1 (Prox 1) and FOXC2 were shown to act as oncogenes by inducing lymphangiogenesis and 
angiogenesis, respectively[29]. FOXC2 was also found to be involved in the regulation of Prox 1 
expression[29]. In the present study, we revealed that the expression of FOXC2 correlated with that of 
VEGF-A and -C. These results suggest that FOXC2 may play pivotal roles in tumor proliferation and 
invasion through VEGF signaling. However, further studies are needed to clarify the relationships between 
FOXC2-VEGF signaling, tumor proliferation, and invasion potential. 
 In conclusion, the present study demonstrated that FOXC2 was associated with tumor proliferation 
and invasion via the FOXC2-VEGF signaling pathway and may be an independent prognostic factor in 
OTSCC patients. Further studies on the expression and function of FOXC2 may offer additional indicators 
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for the diagnosis and treatment of OTSCC patients. 
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Figure Legends 
Figure 1  
Representative immunohistochemical staining for FOXC2, VEGF-A and -C in well-differentiated 
OTSCC. 
(A): Immunohistochemical staining for FOXC2 demonstrating the strong cytoplasmic expression of 
FOXC2 (staining intensity of 3)(x20) and diffuse invasion (B)(x20). (C): Immunohistochemical staining for 
VFGF-A demonstrating the strong cytoplasmic expression of VEGF-A (staining intensity of 3)(x20). (D): 
Immunohistochemical staining for VFGF-C demonstrating the strong cytoplasmic expression of VEGF-C 
(staining intensity of 3)(x20). 
 
Figure 2 
Kaplan-Meier curves for 5-year disease-specific survival analysis.  
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The 5-year disease-specific survival rates according to FOXC2 expression in OTSCC patients were plotted 
(Fig. 2). The high-FOXC2 expression group had a significantly poorer prognosis than that of the 
low-expression group (p<0.001). 
Figure 3 
(A) Representative RT-PCR analysis for FOXC2 in OTSCC cell lines (SAS, SCC25, OSC20, HSC-3, 
HSC-4). The FOXC2/GAPDH intensities are the mean ± SD of triplicate experiments. (B) Relationship 
between FOXC2 mRNA expression and the invasion index (%). FOXC2 expression was associated with 
the invasion index (Pearson’s correlation, r=0854, P=0.066). ●, SAS cells; *, OSC20 cells; ■, HSC-3 cells; 
▲, HSC-4 cells; , SCC25 cells. (C) Relationship between FOXC2 mRNA expression and the growth 
index (%). A correlation was observed between FOXC2 expression and the growth index (Pearson’s 
correlation, r=943, p<0.05). ●, SAS cells; *, OSC20 cells; ■, HSC-3 cells; ▲, HSC-4 cells; , SCC25 
cells. 
 32 
Characteristics Number of samples FOXC2 overexpression(-) FOXC2 overexpression(+) P value
Normal epithelia 10 10 0
squamous cell carcinoma 61 39 22 P＜0.05
Gender
Male 41 26 15 0.776
Female 20 13 7
Age
<65 31 20 11 0.923
≧65 30 19 11
T classification
T1/T2 53 36 17 0.124
T3/T4 8 3 5
N classification
N0 47 32 15 0.315
N1/2 14 7 7
stage classification
I/II 45 31 14 0.229
III/IV 16 8 8
Differentiation
well 55 37 18 0.176
moderate/poor 6 2 4
Pattern of invasion
Grades1/2/3 51 36 15 P＜0.05
Grades 4 10 3 7
Local recurrence
(-) 54 35 19 0.695
(+) 7 4 3
Secondary cervical lymph node 
metastasis
(-) 46 31 15 0.365
(+) 15 8 7
VEGF-A
overexpression (-) 31 29 2 P＜0.001
overexpression (+) 30 10 20
VEGF-C
overexpression (-) 38 34 4 P＜0.001
overexpression (+) 23 5 18
Table 1 Correlation between FOXC2 expression and clinicopathologic features.
Univariate analysis Multivariate analysis
Characteristics Risk ratio 95%CI P value Risk ratio 95%CI P value
Gender (Male vs. Female) 0.4751 0.119-1.902 0.293
Age ( <65 vs. ≧65) 0.5772 0.138-2.421 0.452
T classification (T1/T2 vs. T3/T4) 3.832 0.913-16.086 0.066
N classification (N0 vs. N1/2) 4.727 1.164-19.195 P＜0.05 0.009 0.000-0.787 P＜0.05
Stage classification (stage I/II vs. III/IV) 5.859 1.389-24.711 P＜0.05 220.0 2.595-18652 P＜0.05
Differentiation (well vs. poor/moderate) 3.009 0.603-15.023 0.179
Pattern of invasion (grade1-3 vs. grade 4) 11.625 2.692-50.196 P＜0.01 32.642 1.325-804.1 P＜0.05
Local recurrence (+ vs. -) 6.361 1.509-26.807 P＜0.05 1.313 0474-4.680 P＜0.01
Secondary cervical lymph node metastasis       
(+ vs. -) 3.478 0.866-13.966 0.079
VEGF-A expression (+ vs. -) 8.243 1.013-67.073 P＜0.05 3.683 0.185-73.306 0.371
VEGF-C expression (+ vs. -) 3.155 0.750-13.272 0.117
FOXC2 overexpression (+ vs. -) 17.171 2.089-141.12 P＜0.01 31.233 1.936-503.8 P＜0.05
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